Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Bbm-c101

Preclinical

SShanghai Mianyi Biopharmaceutical Co., Ltd.

2

Indications

2

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Squamous Intraepithelial Lesions of the CervixNot yet recruiting

HPV16/18 PositiveNot yet recruiting

Squamous Intraepithelial Lesions of the CervixPreclinical

Not yet recruiting

HPV16/18 PositivePreclinical

Not yet recruiting

Timeline

Expected Milestones

Q4 2029

PreclinicalNot yet recruiting

Squamous Intraepithelial Lesions of the Cervix

NCT07668960

Q3 2031

PreclinicalNot yet recruiting

HPV16/18 Positive

NCT07714577

Clinical

Trials by Indication[1]

HPV16/18 Positive1 trial

A Investigator-Initiated Exploratory Clinical Study to Evaluate the Safety, Tolerability and Efficacy of Injection BBM-C101 in Subjects With HPV16/18 Infection

Not yet recruiting·TTianjin First Central Hospital·Preclinical·NCT07714577·200 enrolled

Squamous Intraepithelial Lesions of the Cervix1 trial

A Phase I/ IIa, Open-Label, Single-Arm, Dose-Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of BBM-C101 Injection in Patients With Cervical High-Grade Squamous Intraepithelial Lesions.

Not yet recruiting·SShanghai Mianyi Biopharmaceutical Co., Ltd.·Preclinical·NCT07668960·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Bbm-c101. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Bbm-c101. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Shanghai Mianyi Biopharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: SShanghai Mianyi Biopharmaceutical Co., Ltd.

Related News